AGuIX Gadolinium-Based Nanoparticles is under clinical development by NH TherAguix and currently in Phase II for Glioblastoma Multiforme (GBM). According to GlobalData, Phase II drugs for Glioblastoma Multiforme (GBM) have a 23% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how AGuIX Gadolinium-Based Nanoparticles’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

AGuIX Gadolinium-Based Nanoparticles overview

AGuIX is under development for the treatment of metastatic brain tumor, cervical cancer, non-small cell lung cancer, pancreatic cancer, glioblastoma, melanoma, gastrointestinal cancer, HER2 positive breast cancer, and colorectal cancer. The therapeutic candidate is a radiation sensitizer comprising of gadolinium-chelated polysiloxane based nanoparticles. It is administered through intravenous route.

NH TherAguix overview

NH TherAguix is a clinical-stage pharmaceutical company that develops nanomedicine to treat cancer. The company offers AGuIX, a radio sensitizer and radio enhancer drug that contains gadolinium nanoparticles, which help improve the localization of solid tumors and the results of radiation therapy. NH TherAguix’s AGuIX causes an increase in tumor contrast following injection, which enables physicians to localize and identify the tumor region. The company’s pipeline portfolio includes Phase I entities, nanocol for cervical cancer; nanorad for brain metastasis treatment; and other pipeline products for glioblastoma, lung, head, and neck cancers. NH TherAguix is headquartered in Villeurbanne, Auvergne, France.

For a complete picture of AGuIX Gadolinium-Based Nanoparticles’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 20 May 2024

Premium Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.